In vitro determination of hemoglobin A1c for diabetes diagnosis and management: technology update by English, Emma et al.
© 2014 English et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Pathology and Laboratory Medicine International 2014:6 21–31
Pathology and Laboratory Medicine International Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
21
R e v I e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/PLMI.S48403
In vitro determination of hemoglobin A1c  
for diabetes diagnosis and management:  
technology update
emma english1
elise T Milosevich1
w Garry John2
1School of Medicine, University  
of Nottingham, Royal Derby Hospital, 
Derby, United Kingdom; 2Department 
of Clinical Biochemistry, Norfolk 
and Norwich University Hospital, 
Norwich, United Kingdom
Correspondence: w Garry John 
Department of Clinical Biochemistry,  
Norfolk and Norwich University  
Hospital, Norwich, NR4 7UY,  
United Kingdom 
Tel +44 1603 286 933 
Fax +44 1603 286 928 
email g.john@nnuh.nhs.uk
Abstract: It is fascinating to consider the analytical improvements that have occurred since 
glycated hemoglobin was first used in routine clinical laboratories for diabetes monitoring around 
1977; at that time methods displayed poor precision, there were no calibrators or material with 
assayed values for quality control purposes. This review outlines the major improvements in 
hemoglobin A
1c
 (HbA
1c
) measurement that have occurred since its introduction, and reflects on 
the increased importance of this hemoglobin fraction in the monitoring of glycemic control. 
The use of HbA
1c
 as a diagnostic tool is discussed in addition to its use in monitoring the patient 
with diabetes; the biochemistry of HbA
1c
 formation is described, and how these changes to the 
hemoglobin molecule have been used to develop methods to measure this fraction. Standard-
ization of HbA
1c
 is described in detail; the development of the IFCC Reference Measurement 
Procedure for HbA
1c
 has enabled global standardization to be achieved which has allowed global 
targets to be set for glycemic control and diagnosis. The importance of factors that may interfere 
in the measurement of HbA
1c
 are highlighted.
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Introduction
Diabetes mellitus is one of the most common noncommunicable diseases globally, 
affecting an astounding 382 million people worldwide in 2013, and estimated to 
increase to 592 million by 2035. Predominantly, affected individuals are between the 
ages of 40–59 years and 80% of the affected population are in low- and middle-income 
countries. However, the number of individuals with type 2 diabetes continues to rise 
in every country.1
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 
refers to diabetes mellitus as a group of metabolic disorders characterized by the 
presence of hyperglycemia due to defective insulin secretion, insulin action, or both.2 
Additionally, the World Health Organization (WHO) describes diabetes mellitus as a 
metabolic disorder with heterogeneous etiologies determined by chronic hyperglycemia 
and disturbance to carbohydrate, protein, and fat metabolism, which induces the risk 
of microvascular damage.3 The long-term complications of diabetes are extensive, 
with retinopathy leading to vision loss, nephropathy leading to chronic kidney disease, 
and peripheral neuropathy being the most common microvascular complications. In 
addition, cardiovascular disease, peripheral artery disease, and stroke are common 
macrovascular complications.
The American Diabetes Association further classifies diabetes mellitus into four 
categories: type 1, type 2, gestational, and other specific types.2 These classifications 
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replaced the outdated terms “insulin-dependent diabetes 
mellitus”, and “noninsulin-dependent diabetes mellitus”, 
which divided patients according to treatment rather than 
the etiology of their disease process. Type 1 diabetes mel-
litus is a disorder that arises from the destruction of the 
β-cells of the islets of Langerhans through autoimmune 
action or idiopathic mechanisms. The most common form 
of diabetes is type 2 diabetes mellitus, a heterogeneous 
group ranging from primarily insulin resistance and a rela-
tive lack of insulin action, through to a defect in secretion 
with concomitant insulin resistance. The other specific 
types include genetic defects, drug induced, infection 
related, endocrinopathies, and various others. Gestational 
diabetes is a carbohydrate intolerance resulting in hyperg-
lycemia of variable severity with onset or first recognition 
during pregnancy.4
Hemoglobin A1c (HbA1c)  
as a clinical tool
In 1969, Rahbar et al5 made the connection between elevated 
levels of HbA
1c
 and diabetes, and further studies investigated 
this link in a number of small patient cohorts.6,7 Early studies 
indicated that monitoring of HbA
1c
 levels allowed changes 
in therapy and subsequent reduction of measured HbA
1c
 
levels, but did not show that this improved patient outcome.8 
However, there was an evident lack of standardization in 
these studies, both in terms of analytical performance and 
clinical utility. There were no uniform HbA
1c
 target values 
for maintaining blood glucose control; accordingly, there 
was no consensus on whether strict glucose control was 
of benefit in improving patient outcomes. The increase 
in popularity of HbA
1c
 as a marker of glycemic control 
came with the publication of the  Diabetes Control and 
Complications Trial (DCCT)9 and the UK Prospective 
Diabetes Study (UKPDS)10 studies. These large longitudinal 
studies, involving people with type 1 and type 2 diabetes, 
respectively, addressed the question of whether tight control 
of glucose levels in these patients resulted in a decrease in 
complication rates.
The DCCT study was a multicenter, randomized clinical 
trial involving 1,441 people with type 1 diabetes. The study 
was designed to assess if intensive therapy could be used to 
prevent or delay the progression of early vascular or neuro-
logical complications, using retinopathy as the primary study 
outcome. The treatment goal for the conventional therapy 
group was an absence of symptoms attributable to glycosuria 
or hyperglycemia, whereas the intensive therapy group targets 
were near-normal glucose levels.9 
The primary outcome measure of the study was a 
sustained change in levels of retinopathy; over the mean 
follow-up period of 6 years, the intensive therapy reduced 
the adjusted mean risk by 76% (P,0.001).9 
The Epidemiology of Diabetes Interventions and 
 Complications (EDIC) study11 followed the patients enrolled 
in the DCCT study for a further 20 years with no attempt 
to formally continue the original therapy regimes of the 
DCCT study, although mean HbA
1c
 values have converged 
between the two groups as a result of the change in practice 
brought about by the results of the original trial. Data from 
the EDIC follow-on study showed that the reduction in 
risk for any fatal and nonfatal cardiovascular disease event 
(including confirmed angina, or the need for coronary artery 
revascularization) was 42% in intensive versus conventional 
treatment streams and 5% in fatal and nonfatal myocardial 
infarction and stroke.11
The UKPDS study recruited 3,867 newly diagnosed 
patients with type 2 diabetes who were randomized by weight, 
then into conventional and intensive therapy regimes.10 The 
conventional regime aimed to avoid marked hyperglycemia 
(fasting plasma glucose [FPG] .15 mmol/L and/or symp-
toms of hyperglycemia) and was primarily based on diet and 
lifestyle advice alone. The intensive therapy group aimed to 
achieve an FPG of ,6.0 mmol/L with treatment using insulin 
or sulfonylureas. Unlike the DCCT study, a target value of 
HbA
1c
 was not assigned in either of the therapy groups.
In regards to the study endpoints, the reduction in 
microvascular complications was the most significant, 
with a reduction of 25% in the intensive therapy group, 
predominantly attributable to retinopathy (two-stage progres-
sion of disease).10 
After the completion of the UKPDS, the patients contin-
ued to be monitored in a follow-up study to determine if there 
were longer-term effects of the therapy regimes.12 No attempt 
was made to maintain the initial therapy randomization; 
patients were returned to routine care with clinic follow-ups 
for the first 5 years and questionnaires for the following 
5 years. The between-group differences in HbA
1c
 levels 
were lost within the first year of follow-up, but, overall, the 
levels decreased over the time of the post-trial study. This 
may, in part, be due to the implementation of guidelines for 
stricter glycemic control in diabetic patients that arose as 
an outcome to the original study. Results of the follow-up 
showed a 24% risk reduction in microvascular complica-
tions, 15% risk reduction in myocardial infarction (MI), 
and 13% risk reduction for all-cause mortality. This risk 
reduction despite the loss in differences of HbA
1c
 has been 
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termed the “legacy effect”. When the relative risk profiles 
for micro- and macrovascular complications are compared, 
they show a significantly different profile; higher HbA
1c
 
values contribute to a greater proportional risk in cases of 
microvascular disease, but a wider range of HbA
1c
 (includ-
ing lower “nondiabetic”) values contribute to increased risk 
in macrovascular disease. The data from these two seminal 
trials showed that early, intensive therapy could significantly 
reduce the risk of a range of complications, even after the 
initial therapy has been discontinued. Accordingly, these 
studies permitted the establishment of precise target HbA
1c
 
values for treatment goals.
HbA1c as a diagnostic tool
An International Expert Committee, appointed by the 
American Diabetes Association (ADA), the International 
Diabetes Federation (IDF), and the European Association 
for the Study of Diabetes (EASD) published a report in 2009 
recommending the use of glycated hemoglobin (HbA
1c
) for 
the diagnosis of diabetes.13 HbA
1c
 reflects average plasma 
glucose over the previous 8–12 weeks, providing a precise and 
consistent indicator of circulatory glucose levels, allowing for 
accurate assessment of glycemic control as well as the poten-
tial to act as a diagnostic marker of type 2 diabetes. Based on 
the evidence that HbA
1c
 level correlates with adverse disease 
outcomes and the fact that HbA
1c
 targets are used for patient 
treatment, use of HbA
1c
 as a diagnostic tool seemed a logical 
progression. The committee proposed a diagnostic cut-off 
point of 48 mmol/mol (6.5%) HbA
1c
.13
In 2011, the WHO also endorsed the use of HbA
1c
 for 
the diagnosis of type 2 diabetes, stating that HbA
1c
 can be 
used as a diagnostic test provided the following conditions 
are met:
·	 Stringent quality assurance tests are in place
·	 Methods are standardized to the International Reference 
Measurement Procedure
·	 An HbA
1c
 cut point of 48 mmol/mol (6.5%) is recom-
mended for diagnosing diabetes.3
In addition the WHO suggest that a diagnosis of diabetes 
(when based on a glucose criteria) is not excluded if Hba
1c
 
is below 48 mmol/mol (6.5%).3
There are numerous advantages to HbA
1c
 compared 
to glucose testing: HbA
1c
 can be performed at any time 
throughout the day and does not require the patient to fast, 
and HbA
1c
 can avoid the day-to-day variability of glucose 
values, therefore making it the preferred diagnostic test.14–16 
There are, however, various limitations to the use of HbA
1c
 for 
the diagnosis of diabetes linked to several physiological and 
pathological conditions that influence HbA
1c
 concentration. 
HbA
1c
 cannot be used for the diagnosis of diabetes in 
children, for the diagnosis of gestational diabetes, or for 
type 1 diabetes.17 Additionally, HbA
1c
 should not be used for 
the diagnosis or monitoring of patients with diabetes with 
certain hemoglobinopathies or with disorders that affect red 
cell lifespan.18
Biochemistry of HbA1c
The International Federation of Clinical Chemistry and 
Laboratory Medicine (IFCC) committee on Nomenclature, 
Properties and Units defined HbA
1c
 as “Haemoglobin beta 
chain(Blood)-N-(1-deoxyfructos-1-yl)haemoglobin beta 
chain; substance fraction”.19
This definition describes HbA
1c
 as modified hemoglobin, 
with a stable adduct of glucose (covalently linked) to the N-ter-
minal valine of the β-chain. Normal adult hemoglobin consists 
predominantly of HbA (α
2
β
2
), HbA
2
 (α
2
δ
2
), and fetal hemoglo-
bin ([HbF] α
2
γ
2
) (97%, 2.5%, and 0.5% of total hemoglobin, 
respectively). About 6% of total HbA is termed HbA
1
, which 
in turn is made up of HbA
1a1
, HbA
1a2
, HbA
1b
, and HbA
1c
.20 
These fractions are defined by their electrophoretic and chro-
matographic properties, which differ slightly from those of the 
major component HbA
0
, despite the amino acid sequences of 
HbA
1
 and HbA
0
 being identical. HbA
1c
 is the most abundant 
of these minor fractions and comprises approximately 5% of 
the total HbA
1
 fraction. Structural and chemical investiga-
tions elucidated that glucose, in the open chain format, binds 
to the N-terminal to form an aldimine (Schiff base) before 
undergoing an Amadori rearrangement to form a more stable 
ketoamine.21–23 This is a nonenzymatic process that occurs 
continuously in vivo.24 Glycation of hemoglobin occurs pre-
dominantly between glucose and the N-terminal valine of the 
β-chain of hemoglobin to form HbA
1c
.25 In individuals with 
poorly controlled diabetes, the amounts of these glycated 
hemoglobins are greater than in the healthy population.
Methods of HbA1c analysis
The measurement of HbA
1c
 is based on changes that occur 
following glycation of the hemoglobin molecule; glycation of 
the N-terminal residue changes its structure and decreases the 
positive charge of HbA. Methods make use of this  difference 
in charge between HbA
1c
 and HbA
0
, or the  structural 
differences between glycated and nonglycated forms of 
hemoglobin. The slight difference in isoelectric point between 
HbA
1c
 and HbA
0
 allows them to be separated by charge, 
or the presence of the glucose adduct on HbA
1c
 allows for 
the separation by structural difference.26 Thus, methods of 
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HbA
1c
 analysis can be divided into two categories: methods 
based on the charge differences and methods based on the 
structural differences.
Methods based on charge differences
Cation-exchange chromatography
When glucose binds at the beta N-terminal valine of 
hemoglobin to form HbA
1c
, the hemoglobin molecule 
 undergoes a conformational change that results in the mole-
cule presenting with an extra negative charge. This results in 
HbA
1c
 and HbA
0
 having a subtle difference in their isoelectric 
points, allowing them to be separated on this basis.
Cation-exchange chromatography allows for the separation 
of hemoglobin species based on the difference in isoelectric point 
between HbA
1c
 and HbA
0
. Separation is achieved by utilizing 
differences in ionic interactions between the cation exchange 
group on the column resin surface and the hemoglobin com-
ponents in the sample. Ion-exchange chromatographic methods 
include procedures ranging from those that employ disposable 
microcolumns through to high-performance automated systems 
that also quantify several minor hemoglobin species.
Whole-blood samples are diluted with a hemolysis reagent 
to break open the red blood cells and release the hemoglobin 
for analysis. The hemolysate is then injected via an autosampler 
into the analytical column of known volume. A programmed 
buffer gradient of increasing ionic strength (the mobile phase) 
is delivered to the column and the hemoglobins are then sepa-
rated based on their ionic interactions with the column mate-
rial. The stationary phase surface displays negatively charged 
functional groups that interact with positively charged cations 
in the sample; physical characteristics such as surface charge, 
as well as the presence of hydrophilic and hydrophobic groups, 
determine the rate at which each hemoglobin species migrates 
through the column. More highly charged molecules are more 
tightly bound to the resin, and so travel slowly and are eluted 
later, moderately charged molecules equilibrate between the 
resin and the moving buffer more readily, and less charged 
molecules bind less strongly to the resin, equilibrate with 
the moving buffer more readily, and so travel rapidly and are 
eluted sooner. Upon elution from the column, the separated 
hemoglobins pass through the spectrophotometric detector at 
different rates where detection occurs via measured changes 
in the absorbance at a wavelength of 415 nm.
Capillary electrophoresis
Capillary electrophoresis uses the principle of liquid-
flow capillary electrophoresis in free solution. With this 
technique, charged molecules are separated by their 
electrophoretic mobility in an alkaline buffer with a specific 
pH. Separation also occurs according to the electrolyte pH 
and electro-osmotic flow. The separation of the different 
hemoglobin fractions takes place in silica capillary tubes of 
internal diameter ,25 µm, and the migration is performed at 
a high voltage (eg, 9,800 volts) under tight temperature con-
trol using a Peltier device. The high voltages allow for short 
run times and the high surface-to-volume ratio in the capillary 
tube allows for good dissipation of the heat generated. The 
hemoglobins are directly detected at a specific absorption 
wavelength of 415 nm at the cathodic end of the capillary 
using an optical detector. Current automated methods use 
a very small sample size and offer the potential for precise 
separation of different hemoglobin fractions.27
Methods based on structural differences
Immunoassay
The immunoassay technique is based on the binding of 
antibodies targeted against the β-N-terminal glycated 
tetrapeptide or hexapeptide group. Assay design is variable, 
but, in principle, an excess of antibodies, which bind 
 specifically to HbA
1c
, is added to a hemolyzed sample. 
After binding to the HbA
1c
 the excess antibodies agglutinate 
and the resultant turbidity from the immunocomplexes is 
measured using a turbidimeter or nephelometer. In parallel, 
the total hemoglobin concentration is measured bichromati-
cally in the pre-incubation phase.28,29 There are a number 
of commercial assays that are applicable to a broad variety 
of general chemistry analyzers. Immunochemical assays 
are not affected by problems related to electrical charge 
and can be adapted easily for use in the routine medical 
laboratory. However, they all suffer with the general draw-
back of immunochemistry, ie, nonlinear calibration, which 
requires multilevel calibration. As stability of the reagent 
is limited (variably from test to test), relatively frequent 
recalibration is needed. Also, to quantitate HbA
1c
, as a ratio, 
total hemoglobin is measured separately, using a different 
analytical principle that introduces additional uncertainty 
to the outcome.
Affinity chromatography
Affinity chromatography is a separation method that uses a 
biologically/structurally related agent, or “affinity ligand”, 
as a stationary phase to selectively retain analytes or to 
study biological interactions. The affinity ligand can consist 
of a large variety of binding agents, for example, affin-
ity  separation of glycated hemoglobin typically utilizes 
m-aminophenylboronic acid and depends on a specific 
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 interaction between the glucose on glycated hemoglobin and 
the immobilized boronic acid.
A whole-blood sample hemolysate is applied to the 
affinity column and the glycated hemoglobin that contains 
coplanar cis-diol groups interacts strongly with boronic 
acid immobilized on an agarose gel. Ionic and hydrophobic 
forces also contribute to this interaction. The nonglycated 
hemoglobin elutes directly off the column with the first 
buffer. After elution of the nonglycated fraction, bound 
hemoglobin (the glycated fraction) can be dissociated by 
the use of a counter-ligand, which effectively competes 
with bound glycated hemoglobin for the boronic acid sites 
on the gel surface. The absorbance of each of the hemo-
globin fractions can be measured at 415 nm and the ratio 
determined. The results are expressed as a ratio of glycated 
to total hemoglobin.
enzymatic assay
Enzymatic assays utilize proteases to cleave the β-chain 
of hemoglobin to liberate peptides that are then reacted 
in a two-step reaction to quantify HbA
1c
. After lysis, the 
whole-blood samples are subjected to extensive proteolytic 
digestion; this process releases amino acids, including gly-
cated valines, from the hemoglobin β-chains. In the direct 
enzymatic HbA
1c
 assay, glycated valines serve as substrates 
for a specific recombinant fructosyl valine oxidase enzyme. 
The recombinant fructosyl valine oxidase specifically cleaves 
N-terminal valines and produces hydrogen peroxide in the 
presence of selective agents. This, in turn, is measured using 
a horseradish peroxidase catalyzed reaction and a suitable 
chromagen. The signal produced in the reaction is used to 
directly report the %HbA
1c
 of the sample using a suitable lin-
ear calibration curve expressed in %HbA
1c
. Enzymatic assays 
include oxidizing agents in the lysis buffer that react with 
the whole-blood sample to eliminate low-molecular-weight 
and high-molecular-weight signal-interfering substances. 
In parallel, the total hemoglobin concentration is measured 
photometrically.30
Point-of-care testing  
(POCT) devices
The use of POCT has increased dramatically over recent 
years with the advantage of more timely availability of results 
and the subsequent expedient modification of therapy or 
interventions.31 There are several POCT devices available for 
the measurement of HbA
1c
 that are generally based on either 
affinity separation or immunoassay techniques. Performance 
of these analyzers is variable, with some performing as 
well as mainstream larger analyzers and some with poor 
performance. In a recent study, six out of eight POC devices 
tested did not meet accepted analytical performance criteria 
and all showed considerable variability depending on the 
reagent lot numbers used.32
Standardization of HbA1c analysis
The need for standardization
Early HbA
1c
 methods, which were introduced into routine 
practice in the late 1970s, produced significantly different 
results with between-laboratory coefficient of variation (CV) 
values of 11.2%–20.1% observed.33,34 The disparate results 
obtained were because of the range of methods being used 
by laboratories, the lack of standardization, and lack of a 
primary reference material. Although the new generation 
of HbA
1c
 methods now demonstrate a degree of preci-
sion that could not be imagined 30 years ago, comparison 
of results from  different laboratories would remain, at 
best,  difficult – or, more likely, impossible – if not for 
 standardization schemes.
Harmonization
The publication of the DCCT accelerated the need for the 
standardization of HbA
1c
 methods in order to implement safe 
and accurate patient monitoring. Early nationally based sys-
tems include the National Glycohemoglobin Standardization 
Program (NGSP), the Japan Diabetes Society/Japanese 
Society for Clinical Chemistry program, and the Swedish 
standardization program. These national programs achieved 
HbA
1c
 harmonization but, due to the variety of approaches 
used, still yielded variable results.
IFCC standardization and Reference  
Measurement Procedure (RMP)
While these systems provide excellent harmonization of 
HbA
1c
 values, they cannot replace uniform worldwide 
standardization anchored on a metrologically sound 
international reference measurement system comprising:
·	 a clear definition of the analyte based on its molecular 
structure;
·	 a primary reference material containing the analyte in a 
pure form; and 
·	 a validated reference method that specifically measures 
the analyte in human samples.35
In 1995, the IFCC formed its Working Group on HbA
1c
 
Standardization with the objective to develop a reference mea-
surement system for the measurement of HbA
1c
 based on these 
metrological principles.36 The IFCC Working Group decided 
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to base the standardization of HbA
1c
 on the stable adduct 
of glucose to the N-terminal amino group of the β-chain of 
HbA
0
 (N-[1-deoxyfructosyl] hemoglobin). The rationale was 
that HbA
1c
 is biochemically well characterized; is the major 
form of glycated hemoglobin in human blood; and most of 
the commercial glycated hemoglobin tests claim to measure 
this fraction. Even affinity chromatography methods can be 
standardized against an HbA
1c
 comparison method since there 
is a close correlation between the total glycated hemoglobin 
measured by affinity chromatography and HbA
1c
.
The RMP is based on the enzymatic cleavage of the intact 
hemoglobin molecule with endoproteinase Glu-C to obtain 
the β-N-terminal hexapeptides of HbA
1c
 and HbA
0
 (thus 
avoiding the heterogeneity created by modifications of other 
glycation sites of the hemoglobin molecule). The peptides 
are then separated by reverse-phase high-performance liquid 
chromatography, and quantified by electrospray ionization 
mass spectrometry or by capillary electrophoresis. Both 
methods have been proven to be specific for the measured 
defined. The RMP is used to assign values to whole-blood 
panels that serve as calibrators for manufacturers. The 
manufacturers then subsequently use these to assign values 
to the calibrators provided in their kits, providing traceability 
from the patient sample back through the RMP to the defined 
pure materials.
There is no interference from abnormal hemoglobins such 
as sickle-cell hemoglobin (HbS) and HbC and no interference 
from acetylated or carbamylated hemoglobin. Importantly, 
both methods are linear in the clinically relevant concentra-
tion range from 27–97 mmol/mol (2.5%–11%) HbA
1c
.
International network  
of reference laboratories
The RMP is established in a network of 15 reference labo-
ratories located worldwide using either the electrospray 
ionization mass spectrometry or the capillary electro-
phoresis option. The purpose of this network is to assign 
values to a range of standard materials, including the blood 
panels used by manufacturers; the values are assigned 
to the material using the entire network of laboratories, 
rather than individual centers resulting in a very low level 
of uncertainty.
The International HbA1c Consensus  
Committee statement
In order to meet the criteria established by the WHO for the 
diagnosis of diabetes, patient samples should be measured 
using “assays [that] are standardized to criteria aligned 
to the international reference values”,3 which is only rep-
resented by the IFCC RMP. In addition to this, the IFCC 
recommends that the HbA
1c
 concentration of patients should 
be reported in units as per The International System of Units 
(SI). In order to corroborate this, in 2007, an International 
HbA
1c
 Consensus Committee was formed from members 
of the ADA, EASD, IDF, and the IFCC, which agreed a 
consensus statement, which was then updated in 2010.37,38 
The key points highlighted in the consensus statement 
included:
·	 Methods for the measurement of HbA
1c
 should be stan-
dardized to the IFCC Reference System, this is to ensure 
traceability to a defined reference material.
·	 HbA
1c
 values should be reported in SI (Système Interna-
tional) units of mmol/mol and NGSP units (%) should be 
derived using the master equation for the two systems.
·	 In order to facilitate the move to SI units editors are 
strongly recommended to require that manuscripts present 
both units.
·	 HbA
1c
 is the term used to describe glycated hemoglobin 
(GHb) although A
1c
 may also be used in guidelines and 
educational materials.37,38
Master equations for the conversion between IFCC and 
NGSP units are as follows:
 NGSP (%) =(0.0915 × IFCC [mmol/mol]) +	2.15. (1)
 IFCC (mmol/mol) =(10.93 ×	NGSP [%]) -	23.50. (2)
Analytical goals for HbA1c analysis
In clinical practice, clinicians often consider a change 
in value of 5 mmol/mol (0.5%) in successive samples 
as a clinically significant change in the patient’s glyce-
mic control.39  Therefore, the within-laboratory (intra-
laboratory) CV of HbA
1c
 values should be ,3% (,2% 
with NGSP units). The overall between-laboratory (inter-
laboratory) CV should be ,5% (,3.5% with NGSP units) 
and the between- laboratory CV for the same method should 
be ,4.5% (,3% with NGSP units).40 The difference in 
values between the two units (SI and %) is due to the 
measurement of nonspecific interferences in the NGSP 
reference method.41
Analytical interferences  
of HbA1c testing
In certain situations in which hemoglobin variants or adducts 
(derivatives) are present, method-specific interferences may 
occur, and therefore HbA
1c
 could be unreliable. The most 
Pathology and Laboratory Medicine International 2014:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
27
HbA1c technology update
HbA1c methodologies
Charge
Cationexchange
chromatography
Capillary
electrophoresis Immunoassay
IFCC standardization
Affinity
chromatography Enzymatic assay
Structural
Figure 1 Overview of the different methodologies available for the measurement of HbA1c.
Abbreviations: HbA1c, hemoglobin A1c; IFCC, International Federation of Clinical Chemistry and Laboratory Medicine.
common analytical interferences are hemoglobin variants, 
elevated HbF, and hemoglobin adducts.42
Hemoglobin variants
The four most common hemoglobin variants worldwide 
are HbS (high prevalence in black Africans and  Americans, 
 Indians, and people of Mediterranean descent), HbE 
 (Southeast Asians), HbC (black Africans and Americans), 
and HbD (globally distributed); each of these hemoglo-
bins has a single amino acid substitution in the β-chain.43 
These hemoglobin variants can interfere with HbA
1c
 
measurement in different ways depending on the technical 
features of the method used, independently of any effects 
caused by shortened erythrocyte survival.40 Approximately 
900  hemoglobin variants have been identified, many of which 
are clinically silent.29
With hemoglobin variants S, C, D, and E, the amino acid 
substitution results in an alteration of the net charge, which 
will cause interference with charge-based methods of HbA
1c
 
measurement.43 Thus, charge-based methods such as cation-
exchange chromatography and capillary electrophoresis are 
vulnerable to the effect of hemoglobin variants. Modern ana-
lyzers utilizing these methods can often indicate the presence 
of clinically silent hemoglobin variants from the abnormal 
peaks in the chromatograms, but some older-generation 
analyzers may lack the resolution required to differentiate 
between them.44 Inaccurate HbA
1c
 values can result when 
the variant hemoglobin, both glycated and nonglycated, 
cannot be separated from HbA or HbA
1c
; consequently, they 
co-elute or co-migrate with HbA
1c
, leading to a substantial 
overestimation of HbA
1c
.43
Hemoglobin variants may also affect methods based on 
structure, such as with immunoassay-based methods. Since 
these methods utilize antibodies that identify the N-terminal 
glycated amino acids in the first four to ten amino acids of 
the hemoglobin β-chain, any hemoglobin variants, such as 
HbS and HbC, with a mutation involving that particular 
epitope will interfere with HbA
1c
 measurement. In order to 
assess whether an individual analyzer is likely to be affected, 
readers are referred to the NGSP website, where a table of 
assay interferences details current knowledge covering a wide 
range of analyzers.45
An HbA
1c
 deviation of 10.9 mmol/mol (1%) reveals an 
approximate change of 1.4–1.9 mmol/L in average blood 
glucose concentration, therefore an inaccurate HbA
1c
 value 
due to a clinically silent hemoglobin variant can result in 
incorrect treatment for patients.46
HbF
Elevated HbF is another possible interference in the 
measurement of HbA
1c
. HbF contains two α-chains and 
two γ-chains and, in adults, the upper limit of normal is 
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Figure 2 Flow diagram of the IFCC Reference Measurement Procedure for HbA1c.
Abbreviations: Ce, capillary electrophoresis; eSI-MS, electrospray ionization mass 
spectrometry; HbA1c, hemoglobin A1c; IFCC, International Federation of Clinical 
Chemistry and Laboratory Medicine; RP-HPLC, reverse-phase high-performance 
liquid chromatography; m/z, mass-to-charge ratio.
generally around 1%.43 An abnormal increase of HbF may 
occur due to pathologic conditions, such as thalassemia, 
sickle cell disease, leukemia, or a hereditary persistence of 
HbF. As HbF does not have β-chains and the γ-chain has a 
terminal glycine rather than a valine, it can only be glycated 
at lysine residues. Glycation of HbF is approximately one-
third that of HbA.
It is necessary to isolate HbF to reduce the risk of any 
possible interference of HbA
1c
 measurement.47 Currently, 
many of the ion-exchange high-performance liquid chro-
matography methods are able to separate normal level HbF, 
as well as elevated HbF, into a separate peak. Boronate affin-
ity methods, however, are affected by elevated HbF levels, 
as the method measures the ratio of glycated to nonglycated 
hemoglobin, irrespective of the hemoglobin structure, and 
elevated HbF can interfere with the measurement. Results 
may be falsely low due to a lower glycated rate for HbF than 
HbA and the concomitant elution of HbF in the nonglycated 
fraction. In addition, immunoassay results will be similarly 
affected with a decrease of approximately 7 mmol/mol for 
immunoassay and 10 mmol/mol for boronate affinity methods 
per 1% increase in HbF. This interference becomes significant 
at HbF levels exceeding 10%.29
Factors that affect the 
interpretation of HbA1c results
Carbamylation of hemoglobin
In addition to genetic variants, chemical modifications 
of hemoglobin may affect the measurement of HbA
1c
.48 
These modifications may lead to inaccurate HbA
1c
 results, 
particularly when charge-based methods of separation are 
used. The most common derivative is carbamylated hemo-
globin (carbamyl-Hb), which is elevated in uremic patients. 
 Carbamyl-Hb has an isoelectric point similar to that of HbA
1c
 
and can therefore interfere with charge-based methods by 
co-eluting with HbA
1c
 and causing a false overestimation 
of HbA
1c
. In order to maintain accurate HbA
1c
 results, 
carbamyl-Hb must be sufficiently separated from HbA
1c
. 
Additionally, uremic patients are subject to factors that affect 
red cell turnover, such as shortened erythrocyte lifespan in 
hemodialysis patients, which will significantly affect the 
concentration of HbA
1c
. Most modern analyzers separate 
carbamyl-Hb sufficiently well to not cause a significant 
interference.
Acetylation of hemoglobin
Elevated concentrations of acetylated hemoglobin result from 
rare mutations at the NH
2
 terminus of the β-globin chain that 
causes an increase in formation of acetylated  hemoglobin 
in vivo. Exposure of normal hemoglobin to aspirin may 
modify several sites, likely lysine residues on both the 
α- and β-chains of HbA. Acetylation of lysine residues with 
aspirin creates a negative charge on the modified protein. 
This modified hemoglobin has altered electrophoretic and 
chromatographic (ion-exchange) properties, causing it to 
migrate ahead of HbA
0
, like HbA
1
. Although there is in vitro 
evidence to show interference by acetylation, it is ambigu-
ous as to what degree this is a disruption in vivo and to what 
extent, if any, chronic use of aspirin may have an effect on 
HbA
1c
 measurement.49
Labile HbA
Another common derivative is pre-HbA
1c
, or labile HbA.29 
Labile HbA
1c
 is an intermediate in the synthesis of HbA
1c
 
and is characterized by the reversible binding of glucose to 
hemoglobin as a Schiff base.50 The quantity of labile HbA
1c
 
is fairly variable from one patient to another and its biologi-
cal variation correlates to fluctuating glycemic levels. The 
formation of labile HbA
1c
 (as well as the retro reaction back 
to hemoglobin and glucose) proceeds fast, and therefore a 
steady state is reached after a couple of hours. At glucose 
levels of 30 mmol/L, the level of labile HbA
1c
 is 3.5%.51 
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Therefore, sufficient removal of the labile fraction is vital 
for accurate HbA
1c
 measurement.
Reduced lifespan of red blood cells
The lifespan of erythrocytes is a key determinant of hemoglo-
bin concentration, and any condition that shortens erythrocyte 
survival or lowers mean erythrocyte age in patients, as well 
as hemolytic anemia or acute or chronic blood loss, will 
cause inaccurate HbA
1c
 results, regardless of the method 
used. Hemolytic anemia and, in particular, renal anemia can 
lead to HbA
1c
 values that are lower than expected because of 
reduced red cell survival.52,53 However, iron deficiency anemia 
can lead to an inappropriate rise in HbA
1c
, which may fall 
after iron replacement therapy.54,55
Jaundice and hyperlipidemia
Patient samples that are severely icteric may give falsely 
elevated HbA
1c
 values with methods relying on charge sepa-
ration if whole-blood hemolysates are used, since  bilirubin 
migrates with the fast hemoglobin and absorbs at the detect-
ing wavelength. Additionally, hyperlipidemia can also cause 
false elevation of HbA
1c
 depending on the method; lipids elute 
in the first HbA
1c
 fraction and are absorbed at 415 nm.56
vitamins C and e
Another situation in which HbA
1c
 test results may be affected 
is with the use of vitamins C and E, which are reported to, at 
times, underestimate HbA
1c
 values.40 Vitamins C and E may 
reduce the rate of glycation of hemoglobin; however, the 
amount to which this occurs with pharmacological doses is 
unknown. Several cross-sectional studies indicate that there 
is no significant relationship between vitamin C and E and 
HbA
1c
 when taken at a normal clinical dose.57
Aging, ethnicity, and sex
Aging and ethnicity can affect HbA
1c
 results: older non-
diabetic individuals seem to have higher HbA
1c
 values 
than younger people. A meta-analysis of data from the 
 Framingham Offspring Study and the National Health and 
Nutrition Examination Survey showed that, in nondiabetic 
patients, there is an approximate increase of 7 mmol/mol 
HbA
1c
 (0.6%) between the ages of 40 and 70 years.58 This 
suggests that nonglycemic factors may contribute to the 
HbA
1c
–age relationship.
Additionally, HbA
1c
 appears to be higher by a similar 
margin in Afro-Caribbeans than in white Europeans and is 
not explained by differences in glycemia.59 In a meta-analysis 
of data from six different population studies,60 comparison 
of white, black African, and Indian populations displayed 
significant differences in correlation between diagnosis with 
HbA
1c
 $48 mmol/mol and oral glucose tolerance tests. In 
two of the three white populations, over 90% of those with 
a diagnosis of diabetes by oral glucose tolerance test would 
also have an HbA
1c
 $48 mmol/mol, but this fell to 50% and 
62% in black African and Indian populations,  respectively. 
The reasons for these differences in ethnicity are still rela-
tively unclear, and, although there are no current  guidelines 
on interpretation of HbA
1c
 values in relation to race or ethnic-
ity, the evidence suggests that this is an area that warrants 
further investigation.
Although there is no difference in mean HbA
1c
 values 
between males and females, the intraindividual variation is 
greater in females than in males; however, the difference does 
not appear to be significant.14
Conclusion
The science of HbA
1c
 measurement has progressed in huge 
leaps since its first inception and, through the efforts of the 
IFCC, NGSP, and instrument manufacturers, improvements 
are continually being made. It is important from a global 
perspective to strive toward unified standardization of 
measurements and reporting of HbA
1c
 values to enable safe 
and effective patient care. The IFCC RMP represents the 
only valid anchor, and all manufacturers should align to 
this system. Users should be encouraged to ensure that the 
analytical instruments they are using for patient care are 
IFCC-aligned, especially if being used for the diagnosis of 
diabetes.
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